Curated News
By: NewsRamp Editorial Staff
January 12, 2026
Sandoz Targets $600B 'Golden Decade' in Affordable Medicines
TLDR
- Sandoz plans to capture significant market share from over $600 billion in medicines losing exclusivity, positioning investors for advantage in the coming golden decade.
- Sandoz executes its strategy through $1.1 billion in facility investments, 13 biosimilar molecules across 100 countries, and a pipeline targeting 60% of the $322 billion biosimilar opportunity.
- Sandoz aims to make healthcare more accessible by providing affordable medicines for 900 million patient treatments, reducing costs while maintaining quality and safety standards.
- Sandoz pioneered the world's first biosimilar in 2006 and now leads in affordable medicines, with 1,300 products supplied to over 100 countries globally.
Impact - Why it Matters
This news matters because Sandoz's plans to expand access to affordable biosimilars and generics could significantly reduce healthcare costs for patients and systems globally. With over $600 billion worth of medicines losing exclusivity in the next decade, increased competition from companies like Sandoz often leads to lower drug prices, making essential treatments more accessible. This is particularly crucial as healthcare expenses rise worldwide, affecting affordability for chronic conditions and life-saving therapies. Sandoz's focus on streamlining biosimilar development could also accelerate market entry for cheaper alternatives, addressing gaps in treatment availability. For consumers, this means potential savings on prescriptions and improved health outcomes, while for the industry, it drives innovation and efficiency in drug production.
Summary
Sandoz, the global leader in affordable medicines, is poised to capitalize on an unprecedented "golden decade" market opportunity, with CEO Richard Saynor outlining ambitious plans at the 44th Annual J.P. Morgan Healthcare Conference. As a standalone company since 2023, Sandoz has delivered on its commitments, establishing a unique "pure-play" position in biosimilars and generics. The company reports strong momentum, with 2024 sales reaching USD 10 billion and double-digit biosimilar growth, positioning it to capture a significant share of the over USD 600 billion in medicines losing exclusivity in the next decade. Key achievements include a USD 1.1 billion investment in a Slovenian biosimilars production center, acquisition of capabilities in Toulouse, France, and six biosimilar launches in 2025.
With three pillars defining its leadership—global scale supplying 1,300 products to over 100 countries, a reputation for reliable execution, and a team of 20,000 employees—Sandoz is targeting approximately 60% of the USD 322 billion biosimilar opportunity and nearly two-thirds of the USD 340 billion generic opportunity. The company's strategy includes focused loss of exclusivity coverage, with a pipeline of over 400 assets and a longer-term focus on emerging markets like GLP-1s. Sandoz is also addressing the "biosimilar void" by advocating for streamlined development to reduce costs and time to market, aiming to make healthcare more accessible and affordable worldwide.
For more details, view the original release on www.newmediawire.com, which includes access to a webcast and presentation slides from Richard Saynor's presentation. Sandoz's progress, including a mid-term outlook of mid-single-digit annual sales growth to 2028 and core EBITDA margin expansion to 24-26%, underscores its commitment to leading the affordable medicines industry. By leveraging its heritage dating back to 1886 and breakthroughs like the world's first biosimilar in 2006, Sandoz aims to ensure 900 million patient treatments annually, driving substantial healthcare savings and social impact in the coming decade.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Sandoz Targets $600B 'Golden Decade' in Affordable Medicines
